Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Gamma hydroxybutyrate (GHB) intoxication

Deborah L Zvosec, PhD
Stephen W Smith, MD
Section Editors
Stephen J Traub, MD
Michele M Burns, MD, MPH
Deputy Editor
Jonathan Grayzel, MD, FAAEM


GHB is a central nervous system (CNS) depressant that is abused recreationally as a "party drug" or "club drug" with a wide array of formulations, use patterns, and health risks.

GHB was first synthesized in France as an analog of gamma aminobutyric acid (GABA) capable of crossing the blood brain barrier. Initially used as an anesthetic in Europe, GHB was found to have inadequate analgesic effects and significant side effects, including myoclonus and emergence delirium, and did not receive approval in the United States [1]. In the 1980s GHB was marketed as a bodybuilding and weight loss drug and sold in health food stores. Recreational use of GHB subsequently became more widespread as GHB was abused at clubs, raves, and dance venues for euphoric, sexual, stimulant, and relaxant effects.

Following reports of adverse effects from and the enactment of government restrictions on GHB, gamma butyrolactone (GBL) and 1,4 butanediol (BD), two common industrial solvents, became popular as "dietary supplements", and were promoted for bodybuilding, weight loss, sleep, and in the treatment of depression, anxiety, and alcohol and drug dependence. Both GBL and BD are rapidly metabolized to GHB, with the same clinical effects. (See 'Pharmacology and cellular toxicology' below.)

Adverse events from and subsequent regulation of GBL and BD "supplements" led to spurious sale of both compounds as "non-toxic" and "organic" solvents, "cleaning products," and "chemical samples" to avoid detection and prosecution [2]. These products were then replaced by industrial GBL and BD sold on the internet through unregulated companies in Asia and Europe [3]. Analog supplements, such as "Potion 9," have also been spuriously marketed on the internet in recent years as "mood enhancers," promoted primarily for prosexual effects, but with no disclosure of BD on product labels or websites [4].

The toxicology and management of acute GHB intoxication are reviewed here. GHB withdrawal, GHB in the treatment of narcolepsy, the toxicology of other drugs of abuse that may be coingested, and general management of the poisoned patient are all discussed separately. (See "Gamma hydroxybutyrate (GHB) dependence and withdrawal" and "Treatment of narcolepsy in adults", section on 'Sodium oxybate' and "MDMA (ecstasy) intoxication" and "General approach to drug poisoning in adults" and "Initial management of the critically ill adult with an unknown overdose".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Mar 08, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Dyer JE. gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9:321.
  2. Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87.
  3. Pazos D, Giannasi P, Rossy Q, Esseiva P. Combining Internet monitoring processes, packaging and isotopic analyses to determine the market structure: example of Gamma Butyrolactone. Forensic Sci Int 2013; 230:29.
  4. Jury convicts former police officer for selling date rape drug. Press Release, U.S. Attorney's Office, Southern District of New York, Department of Justice, NY 2016.
  5. Drug Abuse Warning Network (DAWN), Drug Abuse Warning Network, 2011. National Estimates of Drug Related Emergency Department Visits. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Administration, Rockville, MD 2013.
  6. van Amsterdam J, Brunt T, Pennings E, van den Brink W. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regul Toxicol Pharmacol 2014; 70:507.
  7. Hillebrand J, Olszewski D, Roumen S. GHB and its precursor GBL: an emerging trend case study. EMCDDA. Lisbon, 2008.
  8. Liechti ME, Kunz I, Greminger P, et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81:323.
  9. Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20:521.
  10. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188:709.
  11. Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol (Phila) 2008; 46:187.
  12. Galicia M, Nogue S, Miró O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011; 28:462.
  13. Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011; 3:417.
  14. Corkery JM, Loi B, Claridge H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 2015; 53:52.
  15. Korf DJ, Nabben T, Benschop A, et al. Risk factors of γ-hydroxybutyrate overdosing. Eur Addict Res 2014; 20:66.
  16. Vallersnes OM, Jacobsen D, Ekeberg Ø, Brekke M. Outpatient treatment of acute poisoning by substances of abuse: a prospective observational cohort study. Scand J Trauma Resusc Emerg Med 2016; 24:76.
  17. Dietze P, Horyniak D, Agius P, et al. Effect of intubation for gamma-hydroxybutyric acid overdose on emergency department length of stay and hospital admission. Acad Emerg Med 2014; 21:1226.
  18. European Drug Report 2016: Trends and Developments. Publications Office of the European Union; European Monitoring Centre for Drugs and Drug Addiction, Luxembourg, 2016.
  19. Netherlands National Drug Monitor. The Netherlands Drug Situation 2014. Trimbos Instituut, Netherlands Institute of Mental Health and Addiction. Utrecht, 2014.
  20. Brunt TM, van Amsterdam JG, van den Brink W. GHB, GBL and 1,4-BD addiction. Curr Pharm Des 2014; 20:4076.
  21. Wood DM, Nicolaou M, Dargan PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse 2009; 44:1495.
  22. Strickland RM, Felgate P, Caldicott DG. Survival of massive gamma-hydroxybutyrate/1,4-butanediol overdose. Emerg Med Australas 2005; 17:281.
  23. Halkitis PN, Palamar JJ. GHB use among gay and bisexual men. Addict Behav 2006; 31:2135.
  24. Carey JW, Mejia R, Bingham T, et al. Drug use, high-risk sex behaviors, and increased risk for recent HIV infection among men who have sex with men in Chicago and Los Angeles. AIDS Behav 2009; 13:1084.
  25. Daskalopoulou M, Rodger A, Phillips AN, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 2014; 1:e22.
  26. Bourne A, Reid D, Hickson F, et al. Illicit drug use in sexual settings ('chemsex') and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect 2015; 91:564.
  27. Couper FJ, Logan BK. GHB and driving impairment. J Forensic Sci 2001; 46:919.
  28. Al-Samarraie MS, Karinen R, Mørland J, Stokke Opdal M. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010; 66:987.
  29. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci Med Pathol 2008; 4:205.
  30. Zvosec DL, Smith SW, Porrata T, et al. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29:319.
  31. Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int J Legal Med 2010; 124:1.
  32. Couper FJ, Logan BK. Addicted to driving under the influence--a GHB/GBL case report. J Anal Toxicol 2004; 28:512.
  33. Barker JC, Karsoho H. Hazardous use of gamma hydroxybutyrate: driving under the influence. Subst Use Misuse 2008; 43:1507.
  34. Wallace DM, Maze T, Shafazand S. Sodium oxybate-induced sleep driving and sleep-related eating disorder. J Clin Sleep Med 2011; 7:310.
  35. Fieguth A, Albrecht K, Weller JP, et al. [First report of lethal gamma-hydroxybutyrate (GHB) intoxication after consumption of gamma-butyrolactone (GBL) in Lower Saxony]. Arch Kriminol 2009; 223:45.
  36. Hérissé AL, Hogan J, Lebourgeois F, et al. [Accidental gamma-hydroxybutyrate poisoning in an infant]. Arch Pediatr 2016; 23:109.
  37. de Knegt VE, Breindahl T, Harboe KM, et al. Gamma-hydroxybutyrate and cocaine intoxication in a Danish child. Clin Case Rep 2016; 4:228.
  38. Piastra M, Barbaro R, Chiaretti A, et al. Pulmonary oedema caused by "liquid ecstasy" ingestion. Arch Dis Child 2002; 86:302.
  39. Savage T, Khan A, Loftus BG. Acetone-free nail polish remover pads: toxicity in a 9-month old. Arch Dis Child 2007; 92:371.
  40. Olives TD, Cole JB. An acutely altered toddler. Pediatr Emerg Care 2014; 30:203.
  41. Suchard J, Nizkorodov S, Wilkinson S. 1,4-Butanediol content of aqua dots children's craft toy beads. J Med Toxicol 2009; 5:120.
  42. Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009; 5:365.
  43. Stillwell ME. Drug-facilitated sexual assault involving gamma-hydroxybutyric acid. J Forensic Sci 2002; 47:1133.
  44. Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010; 24:1281.
  45. Varela M, Nogué S, Orós M, Miró O. Gamma hydroxybutirate use for sexual assault. Emerg Med J 2004; 21:255.
  46. Bosman IJ, Verschraagen M, Lusthof KJ. Toxicological findings in cases of sexual assault in the Netherlands. J Forensic Sci 2011; 56:1562.
  47. Mehling LM, Johansen SS, Wang X, et al. Drug facilitated sexual assault with lethal outcome: GHB intoxication in a six-year-old girl. Forensic Sci Int 2016; 259:e25.
  48. Carter LP. Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault. Drug Test Anal 2011; 3:586.
  49. Akins BE, Miranda E, Lacy JM, Logan BK. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009; 54:495.
  50. Caldicott DG, Chow FY, Burns BJ, et al. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004; 181:310.
  51. Zvosec DL, Smith SW. Commenting on"a review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia," by Kantrowitzet al. Clin Ther 2010; 32:780.
  52. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490.
  53. Jamey C, Kintz P, Martrille L, Raul JS. Fatal Combination with 3-Methylmethcathinone (3-MMC) and Gamma-Hydroxybutyric Acid (GHB). J Anal Toxicol 2016; 40:546.
  54. Aromatario M, Bottoni E, Santoni M, Ciallella C. New "lethal highs": a case of a deadly cocktail of GHB and Mephedrone. Forensic Sci Int 2012; 223:e38.
  55. Wang YG. Xyrem (sodium oxybate) postmarketing adverse event reporting system. Sleep Med 2010; 11:595; author reply 595.
  56. Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:221.
  57. The Internet and drug markets, EMCDDA Insights 21. The Office of the European Union; European Monitoring Centre for Drugs and Drug Addiction, Luxembourg, 2016.
  58. Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721.
  59. Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232.
  60. Couper, FJ, Marinetti, LJ. Gamma hydroxybutyrate: effects on human performance and behavior. Forensic Sci Rev 2002; 14:101.
  61. Zvosec, DL, Smith, SW. Gamma hydroxybutyrate (GHB) addiction and withdrawal. From the GHB Addiction Study (Abstract). Ann Emerg Med 2004; 44:S91.
  62. Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23:316.
  63. Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009; 18:675.
  64. Petrolini VM, Keser E, Vecchio S, et al. Gamma-hydroxybutyrate acute intoxication in Italy: Recreational drug intoxication or medication overdose? Abstract 265. Clin Toxicol 2012; 50:344.
  65. Rossi R, Marsili R, Frati P, et al. A case of ethanol intoxication in an alcoholic abuser under long-term treatment with GHB. Journal of Forensic Toxicology and Pharmacology 2014; 3:1.
  66. Dargan PI, Jayachandran A, Button J, et al. A significant Xyrem® overdose managed conservatively despite high GHB concentrations [Abstract 251]. Clin Toxicol 2008; 46:636.
  67. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430.
  68. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21:507.
  69. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34:231.
  70. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353.
  71. Abanades S, Farré M, Segura M, et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit 2007; 29:64.
  72. Brenneisen R, Elsohly MA, Murphy TP, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625.
  73. Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006; 26:524.
  74. Liechti ME, Quednow BB, Liakoni E, et al. Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol 2016; 81:980.
  75. Abanades S, Farré M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci 2006; 1074:559.
  76. Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007; 81:178.
  77. Haller C, Thai D, Jacob P 3rd, Dyer JE. GHB urine concentrations after single-dose administration in humans. J Anal Toxicol 2006; 30:360.
  78. Abanades S, Farré M, Barral D, et al. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007; 27:625.
  79. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6:93.
  80. Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003; 43:59.
  81. Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012; 50:458.
  82. Grove-White IG, Kelman GR. Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory. Br J Anaesth 1971; 43:113.
  83. Carter LP, Richards BD, Mintzer MZ, Griffiths RR. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 2006; 31:2537.
  84. Van Sassenbroeck DK, De Neve N, De Paepe P, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45:533.
  85. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31:716.
  86. Harraway, T, Stephenson, L. Gamma hydroxybutyrate: The Gold Coast Experience. Emerg Med (Australia) 1999; 11:45.
  88. Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol 2010; 21:332.
  89. Haller C, Thai D, Manktelow TC, et al. Cognitive and mood effects of GHB and ethanol in humans (Abstract). J Tox Clin Tox 2004; 42:762.
  90. Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 2009; 206:141.
  91. Dempsey DA, Meyers M, Fiorentino D, et al. Gamma-hydroxybutyrate (GHB) effects upon driving a car (abstract). Clin Pharmacol Ther 2008; 83:S75.
  92. Steel GC. Clinical application of gamma hydroxybutyric acid as a sleep cover in lumbar epidural block. Proc R Soc Med 1968; 61:825.
  93. Xyrem® (sodium oxybate) oral solution. Available online at: jazzph.isat-tech.com/media/PI.pdf (Accessed on March 19, 2011).
  94. George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. Sleep Med 2010; 11:38.
  95. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27:1327.
  96. Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med 1968; 61:821.
  97. Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002; 67:89.
  98. Zvosec DL, Smith SW. "Acute complications of Gamma hydroxybutyrate addiction (abstract). Acad Emerg Med 2005; 12:S13.
  99. Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39:234.
  100. Couper FJ, Logan BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography--mass spectrometry. J Anal Toxicol 2000; 24:1.
  101. Lora-Tamayo C, Tena T, Rodríguez A, et al. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133:256.
  102. Louagie HK, Verstraete AG, De Soete CJ, et al. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997; 35:591.
  103. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31:723.
  104. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000; 19:47.
  105. Higgins TF Jr, Borron SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996; 14:435.
  106. Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and Jolt: deadly new Internet drugs. Pediatrics 2000; 106:829.
  107. Sporer KA, Chin RL, Dyer JE, Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 2003; 42:3.
  108. Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004; 28:481.
  109. MacKenzie G, Draper H, Barnett G, Wakeel BA. An unconscious man with transient exposure of an accessory pathway. Eur J Emerg Med 2000; 7:295.
  110. Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use--New York and Texas, 1995-1996. MMWR Morb Mortal Wkly Rep 1997; 46:281.
  111. Ross TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995; 21:374.
  112. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156:380.
  113. Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone--Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:137.
  114. Lenz D, Rothschild MA, Kröner L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008; 30:755.
  115. Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990; 39:861.
  116. Hodges B, Everett J. Acute toxicity from home-brewed gamma hydroxybutyrate. J Am Board Fam Pract 1998; 11:154.
  117. Adornato BT, Tse V. Another health food hazard--gamma-hydroxybutyrate-induced seizures. West J Med 1992; 157:471.
  118. Stephens BG, Baselt RC. Driving under the influence of GHB? J Anal Toxicol 1994; 18:357.
  119. Elliott SP. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26:432.
  120. Arneson AH, Goetze J. Dietary supplement or dangerous drug? Two case reports of gamma-butyrolactone toxicity. J Emerg Nurs 2000; 26:425.
  121. Dribben, WH, Kirk, MA. A case of atrial fibrillation associated with GHB ingestion (Abstract). J Tox Clin Tox 2001; 39:315.
  122. Reed MJ, Clegg GR. Paroxysmal sympathetic surge associated with gamma hydroxybutyrate. Eur J Emerg Med 2006; 13:41.
  123. Knudsen, K. Intoxication with gamma-hydroxybutyric acid (GHB) is an increasing social and medical emergency in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:226.
  124. Roberts DM, Smith MW, Gopalakrishnan M, et al. Extreme γ-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011; 58:83.
  125. Ulrich S, Müller V, Keel M, Seebach JD. Sudden leg paralysis in a 26-year-old nurse. Swiss Med Wkly 2005; 135:206; author reply 206.
  126. Personne, M, Landgren, A. GHB intoxications in Sweden (Abstract). J Tox Clin Toxicol 2000; 38:185.
  127. Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442.
  128. O'Toole JG, Kristian MR, Devereux L, Kurien R. Gamma-hydroxybutyrate dependence in a rural setting in Wales. J Subst Abuse 2009; 14:70.
  129. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010; 14:77.
  130. Feldman NT. Sodium oxybate post-marketing surveillance. J Clin Sleep Med 2011; 7:417.
  131. Wang YG, Swick TJ, Carter LP, et al. Sodium oxybate: updates and correction to previously published safety data. J Clin Sleep Med 2011; 7:415.
  132. Warning against use of Xyrem (sodium oxybate) with alcohol or drugs causing respiratory depression. FDA Drug Safety Communication, US Food and Drug Administration, 2010.
  133. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3:560.
  134. Jagerdeo E, Montgomery MA, LeBeau MA. An improved method for the analysis of GHB in human hair by liquid chromatography tandem mass spectrometry. J Anal Toxicol 2015; 39:83.
  135. De Paoli G, Walker KM, Pounder DJ. Endogenous γ-hydroxybutyric acid concentrations in saliva determined by gas chromatography-mass spectrometry. J Anal Toxicol 2011; 35:148.
  136. Bennett MJ, Steiner RR. Detection of gamma-hydroxybutyric acid in various drink matrices via AccuTOF-DART. J Forensic Sci 2009; 54:370.
  137. Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40:781.
  138. Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45:261.
  139. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147.
  140. LeBeau, M. Toxicological investigations of drug-facilitated sexual assaults. Forensic Science Communications 1999; 1:1.